Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sasanlimab combinations in advanced NSCLC
NCT04585815Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Nov 2020
- Primary completion
- May 2023
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 2, open-label trial of sasanlimab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Pfizer. Primary endpoints: Dose-Limiting Toxicities at 28 days, Durable Objective Response Rate and 1 more. Started Nov 2020; status: terminated.
02
Drugs
sasanlimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04585815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04585815.